A drug originally used to treat ovarian cancer has shown promising results in patients with advanced peritoneal cancers during a phase I clinical trial.
Ovarian cancer was found to spread via circulating tumor cells (CTCs) in the bloodstream, homing in on the omentum, a sheet of tissue that covers and supports the abdominal organs. Researchers found that the CTCs rely on HER3 to find their way to omentum.
A new combination of medications for treatment of recurrent ovarian cancer showed improved response rates, increased the rate of tumor shrinkage, and prolonged the time until cancers recurred
For women with recurrent platinum-sensitive ovarian cancer, the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib is more effective than olaparib alone.
Breastfeeding, tubal ligation, and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|